Cargando…

Neurosensory dysfunction: A diagnostic marker of early COVID-19

OBJECTIVE: To describe neurosensory dysfunctions, including hyposmia, hypogeusia, and tinnitus, in patients with COVID-19. METHODS: Clinical characteristics and oropharyngeal swabs were obtained from 86 patients with COVID-19 hospitalized in Guangzhou Eighth People’s Hospital. The chronological anal...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Yujie, Xu, Jiabin, Chu, Mei, Mai, Jianbo, Lai, Niangmei, Tang, Wen, Yang, Tuanjie, Zhang, Sien, Guan, Chenyu, Zhong, Fan, Yang, Liuping, Liao, Guiqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323654/
https://www.ncbi.nlm.nih.gov/pubmed/32615326
http://dx.doi.org/10.1016/j.ijid.2020.06.086
_version_ 1783551809013415936
author Liang, Yujie
Xu, Jiabin
Chu, Mei
Mai, Jianbo
Lai, Niangmei
Tang, Wen
Yang, Tuanjie
Zhang, Sien
Guan, Chenyu
Zhong, Fan
Yang, Liuping
Liao, Guiqing
author_facet Liang, Yujie
Xu, Jiabin
Chu, Mei
Mai, Jianbo
Lai, Niangmei
Tang, Wen
Yang, Tuanjie
Zhang, Sien
Guan, Chenyu
Zhong, Fan
Yang, Liuping
Liao, Guiqing
author_sort Liang, Yujie
collection PubMed
description OBJECTIVE: To describe neurosensory dysfunctions, including hyposmia, hypogeusia, and tinnitus, in patients with COVID-19. METHODS: Clinical characteristics and oropharyngeal swabs were obtained from 86 patients with COVID-19 hospitalized in Guangzhou Eighth People’s Hospital. The chronological analysis method was used to detail neurosensory dysfunction. The cycle threshold (Ct) values were used to approximately indicate viral load. RESULTS: Forty-four (51.2%) patients had neurosensory dysfunction: hyposmia (34, 39.5%), hypogeusia (33, 38.4%), and tinnitus (three, 3.5%). Neurosensory dysfunction was significantly more common in patients under 40 years old (p = 0.001) and women (p = 0.006). Hyposmia and hypogeusia coexisted in 23 (26.7%) patients. The interval between onset of hyposmia and hypogeusia was 0.7 ± 1.46 days. The interval from onset of hyposmia and hypogeusia to typical COVID-19 symptoms was 0.22 ± 4.57 and 0.75 ± 6.77 days; the interval from onset of hyposmia and hypogeusia to admission was 6.06 ± 6.68 and 5.76 ± 7.68 days; and the duration of hyposmia and hypogeusia was 9.09 ± 5.74 and 7.12 ± 4.66 days, respectively. The viral load was high following symptoms onset, peaked within the first week, and gradually declined. CONCLUSIONS: Neurosensory dysfunction tends to occur in the early stage of COVID-19, and it could be used as a marker for the early diagnosis of COVID-19.
format Online
Article
Text
id pubmed-7323654
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
record_format MEDLINE/PubMed
spelling pubmed-73236542020-06-30 Neurosensory dysfunction: A diagnostic marker of early COVID-19 Liang, Yujie Xu, Jiabin Chu, Mei Mai, Jianbo Lai, Niangmei Tang, Wen Yang, Tuanjie Zhang, Sien Guan, Chenyu Zhong, Fan Yang, Liuping Liao, Guiqing Int J Infect Dis Article OBJECTIVE: To describe neurosensory dysfunctions, including hyposmia, hypogeusia, and tinnitus, in patients with COVID-19. METHODS: Clinical characteristics and oropharyngeal swabs were obtained from 86 patients with COVID-19 hospitalized in Guangzhou Eighth People’s Hospital. The chronological analysis method was used to detail neurosensory dysfunction. The cycle threshold (Ct) values were used to approximately indicate viral load. RESULTS: Forty-four (51.2%) patients had neurosensory dysfunction: hyposmia (34, 39.5%), hypogeusia (33, 38.4%), and tinnitus (three, 3.5%). Neurosensory dysfunction was significantly more common in patients under 40 years old (p = 0.001) and women (p = 0.006). Hyposmia and hypogeusia coexisted in 23 (26.7%) patients. The interval between onset of hyposmia and hypogeusia was 0.7 ± 1.46 days. The interval from onset of hyposmia and hypogeusia to typical COVID-19 symptoms was 0.22 ± 4.57 and 0.75 ± 6.77 days; the interval from onset of hyposmia and hypogeusia to admission was 6.06 ± 6.68 and 5.76 ± 7.68 days; and the duration of hyposmia and hypogeusia was 9.09 ± 5.74 and 7.12 ± 4.66 days, respectively. The viral load was high following symptoms onset, peaked within the first week, and gradually declined. CONCLUSIONS: Neurosensory dysfunction tends to occur in the early stage of COVID-19, and it could be used as a marker for the early diagnosis of COVID-19. The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2020-09 2020-06-29 /pmc/articles/PMC7323654/ /pubmed/32615326 http://dx.doi.org/10.1016/j.ijid.2020.06.086 Text en © 2020 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Liang, Yujie
Xu, Jiabin
Chu, Mei
Mai, Jianbo
Lai, Niangmei
Tang, Wen
Yang, Tuanjie
Zhang, Sien
Guan, Chenyu
Zhong, Fan
Yang, Liuping
Liao, Guiqing
Neurosensory dysfunction: A diagnostic marker of early COVID-19
title Neurosensory dysfunction: A diagnostic marker of early COVID-19
title_full Neurosensory dysfunction: A diagnostic marker of early COVID-19
title_fullStr Neurosensory dysfunction: A diagnostic marker of early COVID-19
title_full_unstemmed Neurosensory dysfunction: A diagnostic marker of early COVID-19
title_short Neurosensory dysfunction: A diagnostic marker of early COVID-19
title_sort neurosensory dysfunction: a diagnostic marker of early covid-19
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323654/
https://www.ncbi.nlm.nih.gov/pubmed/32615326
http://dx.doi.org/10.1016/j.ijid.2020.06.086
work_keys_str_mv AT liangyujie neurosensorydysfunctionadiagnosticmarkerofearlycovid19
AT xujiabin neurosensorydysfunctionadiagnosticmarkerofearlycovid19
AT chumei neurosensorydysfunctionadiagnosticmarkerofearlycovid19
AT maijianbo neurosensorydysfunctionadiagnosticmarkerofearlycovid19
AT lainiangmei neurosensorydysfunctionadiagnosticmarkerofearlycovid19
AT tangwen neurosensorydysfunctionadiagnosticmarkerofearlycovid19
AT yangtuanjie neurosensorydysfunctionadiagnosticmarkerofearlycovid19
AT zhangsien neurosensorydysfunctionadiagnosticmarkerofearlycovid19
AT guanchenyu neurosensorydysfunctionadiagnosticmarkerofearlycovid19
AT zhongfan neurosensorydysfunctionadiagnosticmarkerofearlycovid19
AT yangliuping neurosensorydysfunctionadiagnosticmarkerofearlycovid19
AT liaoguiqing neurosensorydysfunctionadiagnosticmarkerofearlycovid19